TheSubway.com Announces Investment Opinion on Nova Pharmaceutical Inc.
WESTON, Fla.--(BUSINESS WIRE)--June 6, 2000--TheSubway.com Announces Investment Opinion on Nova Pharmaceutical Inc. (OTCBB: NOVX).
"Monday's action was encouraging, as very little profit taking on the heals of Friday's historic gains suggests that investors have not abandoned their newfound bullish sentiment. But volume continues to disappoint strategists who would like to see market breadth and volume improve on a sustained basis. The New York Stock Exchange experienced one of its 12 lightest trading days, as only 833 million shares were exchanged. The Nasdaq Stock Market did not fare much better, leveling off at 1.44 billion shares traded. Winners outnumbered losers by 22 to 18 on the Nasdaq, while decliners beat advancers by 16 to 13 on the NYSE." Stated Peter Antipatis. More is available at thesubway.com. 
Nova Pharmaceutical Inc. (OTCBB: NOVX) just announced a strategic alliance to dramatically increase sales.
The alliance provides NOVX with the capability to continually update its site, as well as increase its online presence through search engines and Internet based strategic alliances.
Nova Pharmaceutical Inc is the sole manufacturer, distributor, and marketer of Gold's Gym Nutrition supplements. The Company has twenty-three products under the Gold's Gym trademark.
CRG has just initiated coverage on NOVX. CRG is also planning to initiate an intense campaign to alert new experienced investors of this company. We are expecting NOVX to be trading over the $3.00 mark in the short term.
The Markets Largest Volume Leaders:
JDS Uniphase (NASDAQ: JDSU), LM Erics Tel (NASDAQ: ERICY), Ariba Inc. (NASDAQ: ARBA), Applied Matl. (NASDAQ: AMAT)
TheSubway.com, a wholly owned online asset of Capital Research Group, Inc. (CRG) was developed solely for experienced, risk tolerant investors. Subscribers to TheSubway.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known.
About Capital Research Group Inc.
Through TheSubway.com, Capital Research Group (CRG) introduces what in its opinion are undervalued companies to the investment community. Capital Research Group strives to locate companies with enormous growth potential. CRG is a full service public relations / Investor relations firm. For more information about our products or services, please contact CRG at 954-217-9555 or visit us at thesubway.com
All material herein was prepared by Capital Research Group Inc. (CRG) based upon information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this report, have not approved the statements made in this report. This discussion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed within. This material is for information purposes only and should not be construed as an offer or solicitation of an offer to buy or sell the securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.thesubway.com. CRG has been compensated by one or more of the companies listed herein (50,000 NOVX) for the preparation and distribution of this report. CRG's affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value. CRG intends to sell its shares in the event the shares rise in value. CRG may sell its shares for less than the target price given in its opinion.CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. |
